President, I ask unanimous consent that the text of the bill be printed in the Record.  There being no objection, the text of the bill was ordered to be printed in the Record, as follows:                                S. 2729       Be it enacted by the Senate and House of Representatives of      the United States of America in Congress assembled,     SECTION 1. SHORT TITLE.       This Act may be cited as the ``Addiction Prevention and      Responsible Opioid Practices Act''.     SEC. 2. FEDERAL LICENSURE OF PHARMACEUTICAL REPRESENTATIVES                    WHO PROMOTE CERTAIN OPIOIDS.       Subchapter E of chapter V of the Federal Food, Drug, and      Cosmetic Act (21 U.S.C. 360bbb et seq.) is amended by adding      at the end the following:     ``SEC. 569D. FEDERAL LICENSURE OF PHARMACEUTICAL                    REPRESENTATIVES WHO PROMOTE CERTAIN OPIOIDS.       ``(a) In General.--The Secretary, in consultation with the      Attorney General, shall establish a licensure program for      pharmaceutical representatives described in subsection (b).       ``(b) Licensure Program.--       ``(1) Requirement.--Beginning on January 1, 2020, no      individual described in paragraph (2) may engage in the      marketing or promoting of opioid drugs unless such individual      is licensed under this section.       ``(2) Individuals required to obtain licensure.--An      individual required to obtain a license under this section is      any individual who, on behalf of a drug manufacturer,      engaged, on more than 15 days in a calendar year, in the      marketing or promotion to health care professionals,      including educational or sales communications, meetings or      paid events, and the provision of goods, gifts, and samples,      of any opioid drug (other than methadone) that is listed in      schedule II of section 202(c) of the Controlled Substances      Act.       ``(3) Licensure period.--Each license issued under this      section shall be valid for 3 years, and may be renewed for      additional 3-year periods.       ``(c) Requirements.--An individual required to obtain a      license under this section shall--       ``(1) submit to the Secretary, at such time and in such      manner as the Secretary may require--       ``(A) such information as the Secretary may require; and       ``(B) a registration fee in the amount of $3,000;       ``(2) certify that such individual has completed training      on ethics, pharmaceutical marketing regulations, the `CDC      Guidelines for Prescribing Opioids for Chronic Pain',      published by the Centers for Disease Control and Prevention      in 2016 (or any successor document) or the `FDA Blueprint for      Prescriber Education for Extended-Release and Long-Acting      Opioid Analgesics', and applicable Federal laws pertaining to      drug marketing, labeling, and clinical trials, as the      Secretary may require;       ``(3) certify that such individual will not engage in any      illegal, fraudulent, misleading, or other deceptive marketing      of schedule II opioid drugs; and       ``(4) file with the Secretary annual reports disclosing the      names of providers visited and any drug samples or gifts such      individual gives any such provider.       ``(d) Manufacturer Reporting Requirements.--The      manufacturer who employs or contracts with any individual      required to obtain a license under this section shall include      in reports required under section 1128G     of the Social Security Act the name of each such licensed      individual that provides payments or other transfers of value      required to be reported under such section 1128G that relates      to an opioid drug that is listed in schedule II of the      Controlled Substances Act.''.     SEC. 3. WITHDRAWAL OF APPROVAL OF CERTAIN OPIOIDS.       (a) In General.--Notwithstanding any other provision of      law, any ultra-high-dose opioid shall be considered a drug      that presents an imminent hazard to the public health within      the meaning of section 505(e) of the Federal Food, Drug, and      Cosmetic Act (21 U.S.C. 355(e)), and the Secretary of Health      and Human Services shall suspend the approval of such drug,      in accordance with such section 505(e).       (b) Definition.--In this section, the term ``ultra-high-     dose opioid'' means an opioid drug for which the daily dosage      provided for in the approved label exceeds the morphine      milligram equivalents per day outlined in the report entitled      ``CDC Guidelines for Prescribing Opioids for Chronic Pain'',      published by the Centers for Disease Control and Prevention      in 2016 (or any successor document).     SEC. 4. EXPANDING AVAILABILITY OF INFORMATION IN THE ARCOS                    DATABASE.       Section 307(d) of the Controlled Substances Act (21 U.S.C.      827(d)) is amended by adding at the end the following:       ``(3) The Attorney General shall make available to the      medical licensing board and board of pharmacy for each State      the information in the Automation of Reports and Consolidated      Orders System, or any subsequent automated system developed      by the Attorney General to monitor the sale, delivery, and      disposal of controlled substances within such State.''.     SEC. 5. CONTINUING MEDICAL EDUCATION AND PRESCRIPTION DRUG                    MONITORING PROGRAM REGISTRATION FOR                    PRESCRIBERS.       Section 303 of the Controlled Substances Act (21 U.S.C.      823) is amended by adding at the end the following:       ``(k)(1) The Attorney General shall not register, or renew      the registration of, a practitioner under subsection (f) who      is licensed under State law to prescribe controlled      substances in schedule II, III, or IV, unless the      practitioner submits to the Attorney General, for each such      registration or renewal request, a written certification      that--       ``(A)(i) the practitioner has, during the 1-year period      preceding the registration or renewal request, completed a      training program described in paragraph (2); or       ``(ii) the practitioner, during the applicable registration      period, will not prescribe such controlled substances in      amounts in excess of a 72-hour supply (for which no refill is      available); and       ``(B) the practitioner has registered with the prescription      drug monitoring program of the State in which the      practitioner practices, if the State has such program.       ``(2) A training program described in this paragraph is a      training program that--       ``(A) follows the best practices for pain management, as      described in the `Guideline for Prescribing Opioids for      Chronic Pain' as published by the Centers for Disease Control      and Prevention in 2016, or any successor thereto, or the `FDA      Blueprint for Prescriber Education for Extended-Release and      Long-Acting Opioid Analgesics' as published by the Food and      Drug Administration in 2017, or any successor thereto;       ``(B) includes information on--       ``(i) recommending non-opioid and non-pharmacological      therapy;       ``(ii) establishing treatment goals and evaluating patient      risks;       ``(iii) prescribing the lowest dose and fewest number of      pills considered effective;       ``(iv) addictive and overdose risks of opioids;       ``(v) diagnosing and managing substance use disorders,      including linking patients to evidence-based treatment;       ``(vi) identifying narcotics-seeking behaviors; and       ``(vii) using prescription drug monitoring programs; and       ``(C) is approved by the Secretary of Health and Human      Services.''.     SEC. 6. REPORT ON PRESCRIBER EDUCATION COURSES FOR MEDICAL                    AND DENTAL STUDENTS.       Each school of medicine, school of osteopathic medicine,      and school of dentistry participating in a program under      title IV of the Higher Education Act of 1965 (20 U.S.C. 1070a      et seq.), as a condition for such participation, shall submit      an annual report to the Secretary of Education and the      Secretary of Health and Human Services on any prescriber      education courses focused specifically on pain management and      responsible opioid prescribing practices that such school      requires students to take, and whether such courses are      consistent with the most recently published version of the      ``Guideline for Prescribing Opioids for Chronic Pain'' of the      Centers for Disease Control and Prevention or the ``FDA      Blueprint for Prescriber Education for Extended-Release and      Long-Acting Opioid Analgesics'', as published by the Food and      Drug Administration in 2017. The Secretary of Education and      the Secretary of Health and Human Services shall compile the      reports submitted by such schools and submit an annual      summary of such reports to Congress.     SEC. 7. REQUIREMENTS UNDER PRESCRIPTION DRUG MONITORING                    PROGRAMS.       (a) In General.--Beginning 1 year after the date of      enactment of this Act, each State that receives funding under      any of the programs described in subsection (c) shall--       (1) require practitioners, or their designees, in the State      to consult the database of the prescription drug monitoring      program before writing prescriptions for controlled      substances (as such term is defined in section 102 of the      Controlled Substances Act (21 U.S.C. 802)) in schedule II,      III, or IV under section 202 of such Act (21 U.S.C. 812);       (2) require dispensers of controlled substances in schedule      II, III, or IV, or their designees, to input data into the      database of the prescription drug monitoring program within      24 hours of filling a qualifying prescription, as required by      the Attorney General and the Secretary of Health and Human      Services, including patient identifier information, the      national drug code of the dispensed drug, date of dispensing      the drug, quantity and dosage of the drug dispensed, form of      payment, Drug Enforcement Administration registration number      of the practitioner, Drug Enforcement Administration      registration number of the dispenser;       (3) allow practitioners and dispensers to designate other      appropriate individuals to act as agents of such      practitioners and dispensers for purposes of obtaining and      inputing data from the database for purposes of complying      with paragraphs (1) and (2), as applicable;       (4) provide informational materials for practitioners and      dispensers to identify and refer patients with possible      substance use disorders to professional treatment      specialists;       (5) establish formal data sharing agreements to foster      electronic connectivity with the prescription drug monitoring      programs of each State (if such State has such a program)      with which the State shares a border, to facilitate the      exchange of information through an established technology      architecture that ensures common data standards, privacy      protection, and secure and streamlined information sharing;       (6) notwithstanding section 399O(f)(1)(B) of the Public      Health Service Act (42 U.S.C. 280g-3(f)(1)(B)), authorize      direct access to the State's database of the prescription      drug monitoring program to all State law enforcement      agencies, State boards responsible for the licensure,      regulation, or discipline of practitioners, pharmacists, or      other persons authorized to prescribe, administer, or      dispense controlled substances; and       (7) in order to enhance accountability in prescribing and      dispensing patterns, not fewer than 4 times per year,      proactively provide informational reports on aggregate trends      and individual outliers, based on information available      through the State prescription drug monitoring program to--       (A) the State entities and persons described in paragraph      (6); and       (B) the Medicaid agency and the department of public health      of the State.       (b) Transparency in Prescribing Practices and Intervention      for High Prescribers.--       (1) State reporting requirement.--Each State that receives      funding under any of the programs described in subsection (c)      shall, twice per year, submit to the Secretary of Health and      Human Services and the Administrator of the Drug Enforcement      Administration--       (A) a list of all practitioners and dispensers who, in the      applicable reporting period, have prescribed or dispensed      schedule II, III, or IV opioids in the State;       (B) the amount of schedule II, III, or IV opioids that were      prescribed and dispensed by each individual practitioner and      dispenser described in subparagraph (A); and       (C) any additional information that the Secretary and      Administrator may require to support surveillance and      evaluation of trends in prescribing or dispensing of schedule      II, III, or IV opioids, or to identify possible non-medical      use and diversion of such substances.       (2) Annual report.--Not later than 1 year after the date of      enactment of this Act, and annually thereafter, the Secretary      of Health and Human Services, in consultation with the      Administrator of the Drug Enforcement Administration, the      Secretary of Defense, the Secretary of Veterans Affairs, and      the Director of the Indian Health Service, shall submit to      Congress, and make public, a report identifying outliers      among the medical specialties and geographic areas with the      highest rates of opioid prescribing in the Nation, by zip      code.       (3) Development of action plan.--       (A) Initial plan.--Not later than 1 year after the date of      enactment of this Act, the Secretary of Health and Human      Services, in consultation with the Administrator of the Drug      Enforcement Administration, the Secretary of Defense, the      Secretary of Veterans Affairs, and the Director of the Indian      Health Service, shall submit to Congress a plan of action,      including warning letters and enforcement mechanisms, for      addressing outliers in opioid prescribing practices and      ensuring an adequate Federal response to protect the public      health.       (B) Updated plan.--The Secretary of Health and Human      Services shall submit to Congress updates to the plan of      action described in subparagraph (A), as such Secretary, in      consultation with the heads of agencies described in such      subparagraph, determines appropriate.       (c) Programs Described.--The programs described in this      subsection are--       (1) the Harold Rogers Prescription Drug Monitoring Program      established under the Departments of Commerce, Justice, and      State, the Judiciary, and Related Agencies     Appropriations Act, 2002 (Public Law 107-77; 115 Stat. 748);       (2) the controlled substance monitoring program under      section 399O of the Public Health Service Act (42 U.S.C.      280g-3);       (3) the Prescription Drug Overdose: Prevention for States      program of the Centers for Disease Control and Prevention;       (4) the Prescription Drug Overdose: Data-Driven Prevention      Initiative of Centers for Disease Control and Prevention;       (5) the Enhanced State Opioid Overdose Surveillance program      of the Centers for Disease Control and Prevention;       (6) the opioid grant program under section 1003 of the 21st      Century Cures Act (Public Law 114-255); and       (7) the State Opioid Response Grant program described under      the heading ``substance abuse treatment'' under the heading      ``Substance Abuse and Mental Health Services Administration''      of title II of division H of the Consolidated Appropriations      Act, 2018 (Public Law 115-141).       (d) Definitions.--In this section, the terms ``dispenser''      and ``practitioner'' have the meanings given such terms in      section 102 of the Controlled Substances Act (21 U.S.C. 802).     SEC. 8. INTEROPERABILITY OF CERTIFIED HEALTH INFORMATION                    TECHNOLOGY.       Section 3001(c)(5) of the Public Health Service Act (42      U.S.C. 300jj-11(c)(5)) is amended by adding at the end the      following:       ``(F) Interoperability.--Beginning on January 1, 2021, the      National Coordinator shall not certify electronic health      records as health information technology that is in      compliance with applicable certification criteria under this      paragraph unless such technology is interoperable with the      prescription drug monitoring programs of each State that, at      the time of the request for such certification, has such a      program.''.     SEC. 9. STUDIES RELATED TO OVERDOSE DISCHARGE AND FOLLOW-UP                    POLICIES.       (a) Study.--Not later than January 1, 2021, the Secretary      of Health and Human Services shall--       (1) conduct a study on the scope and circumstances of non-     fatal opioid overdoses, the policies and procedures that      States, health care systems, and first responders have      implemented; and       (2) in partnership with stakeholder organizations with      subject matter expertise, establish guidelines for hospital      procedures following non-fatal opioid overdose and the      administration of overdose reversal medication.       (b) Study and Development of Quality Measures Under      Medicare Related to Opioid Abuse and Substance Use      Disorder.--Section 1890A(e) of the Social Security Act (42      U.S.C. 1395aaa-1(e)) is amended--       (1) by striking ``Measures.--The Administrator'' and      inserting ``Measures.--       ``(1) In general.--The Administrator''; and       (2) by adding at the end the following new paragraph:       ``(2) Study and development of quality measures related to      opioid abuse and substance use disorder.--Beginning not later      than 1 year after the date of enactment of this paragraph,      the Administrator of the Center for Medicare and Medicaid      Services shall study and through contracts develop, in      coordination with appropriate subject matter organizations      (such as the entity with a contract under section 1890), for      use under this Act, quality measures related to standards of      care for treating individuals with non-fatal opioid overdose,      discharge procedures, and linkages to appropriate substance      use disorder treatment and community support services.''.     SEC. 10. MEDICAID OPIOID DRUG MAPPING TOOL.       (a) In General.--The Secretary of Health and Human Services      shall create an interactive opioid drug mapping tool, which      shall be made publicly available on the internet website of      the Centers for Medicare & Medicaid Services, showing      prescribing practices of providers that participate in State      Medicaid programs and geographic comparisons, at the State,      county, and ZIP code levels, of de-identified opioid      prescription claims made under State Medicaid programs under      title XIX of the Social Security Act (42 U.S.C. 1396 et      seq.).       (b) Collection of Data From States.--The Secretary of      Health and Human Services may request from States such data      as the Secretary determines necessary to create the opioid      mapping tool described in subsection (a).     SEC. 11. NATIONAL ACADEMY OF MEDICINE STUDY.       (a) Study.--The Secretary of Health and Human Services      shall enter into a contract with the National Academy of      Medicine to carry out a study on the addition of coverage      under the Medicare program under title XVIII of the Social      Security Act of alternative treatment modalities (such as      integrative medicine, including acupuncture and exercise      therapy, neural stimulation, biofeedback, radiofrequency      ablation, and trigger point injections) furnished to Medicare      beneficiaries who suffer from acute or chronic lower back      pain. Such study shall, pursuant to the contract under this      paragraph, include an analysis of--       (1) scientific research on the short-term and long-term      impact of the addition of such coverage on clinical efficacy      for pain management of such beneficiaries;       (2) whether the lack of Medicare coverage for alternative      treatment modalities impacts the volume of opioids prescribed      for beneficiaries; and       (3) the cost to the Medicare program of the addition of      such coverage to treat pain and mitigate the progression of      chronic pain, as weighed against the cost of opioid use      disorder, overdose, readmission, subsequent surgeries, and      utilization and expenditures under parts B and D of such      title.       (b) Report.--Not later than 1 year after the date of      enactment of this Act, pursuant to the contract under      subsection (a), the National Academy of Medicine shall submit      to Congress a report on the study under subsection (a).       (c) Authorization of Appropriations.--To carry out this      section, there are authorized to be appropriated such sums as      may be necessary.     SEC. 12. EXCISE TAX ON OPIOID PAIN RELIEVERS.       (a) In General.--Subchapter E of chapter 32 of the Internal      Revenue Code of 1986 is amended by adding at the end the      following new section:     ``SEC. 4192. OPIOID PAIN RELIEVERS.       ``(a) In General.--There is hereby imposed on the      manufacturer or producer of any taxable active opioid a tax      equal to the amount determined under subsection (b).       ``(b) Amount Determined.--The amount determined under this      subsection with respect to a manufacturer or producer for a      calendar year is 1 cent per milligram of taxable active      opioid in the production or manufacturing quota determined      for such manufacturer or producer for the calendar year under      section 306 of the Controlled Substances Act (21 U.S.C. 826).       ``(c) Taxable Active Opioid.--For purposes of this      section--       ``(1) In general.--The term `taxable active opioid' means      any controlled substance (as defined in section 102 of the      Controlled Substances Act (21 U.S.C. 802), as in effect on      the date of the enactment of this section) manufactured in      the United States which is opium, an opiate, or any      derivative thereof.       ``(2) Exclusions.--       ``(A) Other ingredients.--In the case of a product that      includes a taxable active opioid and another ingredient,      subsection (a) shall apply only to the portion of such      product that is a taxable active opioid.       ``(B) Drugs used in addiction treatment.--The term `taxable      active opioid' shall not include any controlled substance (as      so defined) which is used exclusively for the treatment of      opioid addiction as part of a medication-assisted      treatment.''.       (b) Clerical Amendments.--       (1) The heading of subchapter E of chapter 32 of the      Internal Revenue Code of 1986 is amended by striking      ``Medical Devices'' and inserting ``Other Medical Products''.       (2) The table of subchapters for chapter 32 of such Code is      amended by striking the item relating to subchapter E and      inserting the following new item:               ``subchapter e. other medical products''.       (3) The table of sections for subchapter E of chapter 32 of      such Code is amended by adding at the end the following new      item:``Sec. 4192. Opioid pain relievers.''.       (c) Effective Date.--The amendments made by this section      shall apply to calendar years beginning after the date of the      enactment of this Act.     SEC. 13. OPIOID CONSUMER ABUSE REDUCTION PROGRAM.       (a) Opioid Take-back Program.--Section 302 of the      Controlled Substances Act (21 U.S.C. 822) is amended by      adding at the end the following:       ``(h)(1) The Attorney General shall establish a national      take-back program for the safe and environmentally      responsible disposal of controlled substances.       ``(2) In establishing the take-back program required under      paragraph (1), the Attorney General--       ``(A) shall consult with the Secretary and the      Administrator of the Environmental Protection Agency; and       ``(B) may coordinate with States, law enforcement agencies,      water resource management agencies, manufacturers,      practitioners, pharmacists, public health entities,      transportation and incineration service contractors, and      other entities and individuals, as appropriate.       ``(3) The take-back program established under paragraph      (1)--       ``(A) shall--       ``(i) ensure appropriate geographic distribution so as to      provide--       ``(I) reasonably convenient and equitable access to      permanent take-back locations, including not less than 1      disposal site for every 25,000 residents and not less than 1      physical disposal site per town, city, county, or other unit      of local government, where possible; and       ``(II) periodic collection events and mail-back programs,      including public notice of such events and programs, as a      supplement to the permanent take-back locations described in      subclause (I), particularly in areas in which the provision      of access to such locations at the level described in that      subclause is not possible;       ``(ii) establish a process for the accurate cataloguing and      reporting of the quantities of controlled substances      collected; and       ``(iii) include a public awareness campaign and education      of practitioners and pharmacists; and       ``(B) may work in coordination with State and locally      implemented public and private take-back programs.       ``(4) From time to time, beginning in the second calendar      year that begins after the date of enactment of this      subsection, the     Secretary of the Treasury shall transfer from the general      fund of the Treasury an amount equal to one-half of the total      amount of taxes collected under section 4192 of the Internal      Revenue Code of 1986 to the Attorney General to carry out      this subsection. Amounts transferred under this subparagraph      shall remain available until expended.''.       (b) Funding of Substance Abuse Programs.--From time to      time, beginning in the second calendar year that begins after      the date of enactment of this Act, the Secretary of the      Treasury shall transfer from the general fund of the Treasury      an amount equal to one-half of the total amount of taxes      collected under section 4192 of the Internal Revenue Code of      1986, as added by this Act, to the Director of the Center for      Substance Abuse Treatment of the Substance Abuse and Mental      Health Services Administration for programs of the Center,      including the Block Grants for Prevention and Treatment of      Substance Abuse program under subpart II of part B of title      XIX of the Public Health Service Act (42 U.S.C. 300x-21 et      seq.) and Programs of Regional and National Significance.      Amounts transferred under this subsection shall remain      available until expended.     SEC. 14. GAO STUDY.       Not later than 1 year after the date of enactment of this      Act, the Comptroller General of the United States shall      conduct a study evaluating the various State laws, commercial      insurance methods, and existing research on requirements that      place limitations on opioid prescribing practices and provide      analysis on best practices to address over-prescribing of      opioids, while ensuring that individuals who need such      opioids can access them safely. Such study shall provide      recommendations, including with respect to--       (1) requiring non-opioid pain treatments to be front line      therapies;       (2) limiting first-time opioid prescriptions to a patient      for acute pain to a 72-hour supply; and       (3) pain management treatment contracts between      practitioners and patients that establish informed consent      regarding the expectations, risks, long-term effects, and      benefits of the course of opioid treatment, treatment goals,      the potential for opioid misuse, abuse, or diversion, and      requirements and responsibilities of patients, such as      submitting to a urine drug screening.                                 ______                                       By Mr. McCONNELL:  S. 2730. A bill to amend the Public Health Service Act to establish a pilot program to help individuals in recovery from a substance use disorder transition from treatment to independent living and the workforce, and for other purposes; to the Committee on Health, Education, Labor, and Pensions.  Mr. McCONNELL. Mr. President, I ask unanimous consent that the text of the bill be printed in the Record.  There being no objection, the text of the bill was ordered to be printed in the Record, as follows:                                S. 2730       Be it enacted by the Senate and House of Representatives of      the United States of America in Congress assembled,     SECTION 1. SHORT TITLE.       This Act may be cited as the ``Comprehensive Addiction      Recovery through Effective Employment and Reentry Act'' or      the ``CAREER Act''.     SEC. 2. PILOT PROGRAM TO HELP INDIVIDUALS IN RECOVERY FROM A                    SUBSTANCE USE DISORDER TRANSITION TO                    INDEPENDENT LIVING AND THE WORKFORCE.       Part B of title III of the Public Health Service Act (42      U.S.C. 243 et seq.) is amended by adding at the end the      following:     ``SEC. 320B. PILOT PROGRAM TO HELP INDIVIDUALS IN RECOVERY                    FROM A SUBSTANCE USE DISORDER TRANSITION TO                    INDEPENDENT LIVING AND THE WORKFORCE.       ``(a) In General.--The Secretary shall establish a pilot      program to award 5-year grants under subsection (b)(1) to      States, and 1-year grants under subsection (b)(2) to States      or Indian tribes, for the purpose of making subgrants to      entities under subsection (c) to help individuals in recovery      from a substance use disorder transition from treatment to      independent living and the workforce.       ``(b) Grants.--       ``(1) 5-year grants.--       ``(A) In general.--The Secretary shall award 5-year grants      under this paragraph to 5 States that submit an application      under paragraph (3). Such States shall be selected--       ``(i) from among the 10 States with the highest rate of      death due to drug overdose per 100,000 people, based on data      from the Centers for Disease Control and Prevention for      calendar years 2013 through 2017; and       ``(ii) based on the merits of the proposal included in such      application and the preferences described in subparagraph      (B).       ``(B) Preferences.--The Secretary, in selecting States for      a grant under this paragraph, shall give priority to States      from among the States described in subparagraph (A) with the      combination of--       ``(i) the highest average rates of unemployment based on      data provided by the Bureau of Labor Statistics for calendar      years 2013 through 2017;       ``(ii) the lowest average labor force participation rates      based on data provided by the Bureau of Labor Statistics for      calendar years 2013 through 2017; and       ``(iii) the highest prevalence of opioid use disorder based      on data provided by the Substance Abuse and Mental Health      Services Administration for calendar years 2013 through 2017      as may be available.       ``(C) Grant funds.--       ``(i) In general.--The funds from a 5-year grant awarded      under this paragraph shall be provided to each of the 5      selected States on an annual basis for each of fiscal years      2019 through 2023.       ``(ii) Carry over.--       ``(I) In general.--The funds awarded under clause (i) for a      fiscal year shall remain available for the State to make      subgrants under subsection (c) for such fiscal year, except a      State may carry over (subject to subclause (II)) not more      than 10 percent of such funds for the following fiscal year      for such purpose.       ``(II) Request.--A State may make a request to the      Secretary to carry over more than 10 percent of the funds      awarded under clause (i) for a fiscal year for the following      fiscal year for such purpose, and the Secretary may grant      such request as the Secretary determines appropriate.       ``(III) Amount for following fiscal year.--Any amount      carried over under this clause shall not impact the amount of      the funds the Secretary awards the State for such following      fiscal year.       ``(iii) Return of funds.--Any funds awarded under clause      (i) that are not expended during the fiscal year for which      the funds are awarded and that are not carried over for the      following fiscal year under clause (ii) shall be returned to      the Secretary to carry out this section. Any funds returned      to the Secretary after fiscal year 2023 shall be returned to      the general fund of the Treasury.       ``(2) 1-year grants.--       ``(A) In general.--The Secretary shall, for each of fiscal      years 2019 through 2023, award 1-year grants to States or      Indian tribes under this paragraph that submit an application      in accordance with paragraph (3). Such States or Indian      tribes shall be selected for a grant under this paragraph      based on criteria established by the Secretary.       ``(B) Grant funds.--       ``(i) In general.--The funds awarded through a grant under      subparagraph (A) for a fiscal year shall remain available for      the State or Indian tribe to make subgrants under subsection      (c) for such fiscal year and may not be carried over for such      following fiscal year.       ``(ii) Return of funds.--Any funds awarded through a grant      under subparagraph (A) that are not expended during the      fiscal year of the grant shall be returned to the Secretary      to carry out this section. Any funds returned to the      Secretary after fiscal year 2023 shall be returned to the      general fund of the Treasury.       ``(3) Applications.--       ``(A) In general.--Each State desiring a grant under      paragraph (1) and each State or Indian tribe desiring a grant      under paragraph (2) shall submit an application to the      Secretary at such time and in such manner as the Secretary      may reasonably require for such grant.       ``(B) Contents.--       ``(i) In general.--An application submitted under      subparagraph (A) shall contain such information as the      Secretary may reasonably require, including a proposal for      awarding subgrants under subsection (c) and a method for      evaluating such subgrants.       ``(ii) 5-year grants.--An application submitted under      subparagraph (A) for a grant awarded under subsection (b)(1)      shall include an assurance that not less than 50 percent of      the funds awarded through the grant will be used towards      making subgrants under subsection (c) to the entities      applying for such subgrants that serve the areas in the State      with the highest prevalence of substance use disorder, based      on data determined appropriate by the Secretary.       ``(c) Subgrants.--       ``(1) In general.--Each State that receives a grant under      subsection (b)(1) and each State or Indian tribe that      receives a grant under subsection (b)(2) shall award      subgrants on a competitive basis to entities that meet the      requirements under paragraphs (2) and (3).       ``(2) Subgrant requirements.--       ``(A) Application.--An entity that desires a subgrant under      this subsection shall submit an application to the State or      Indian tribe at such time and in such manner as the State or      Indian tribe may reasonably require.       ``(B) Contents.--An application submitted under      subparagraph (A) by an entity shall contain such information      as the State or Indian tribe may reasonably require,      including a demonstration that the entity has one or more of      the following abilities:       ``(i) The ability to partner with local stakeholders, which      may include local employers, community stakeholders, and      local and State governments, to identify gaps in the      workforce due to the prevalence of substance use disorders.       ``(ii) The ability to partner with local stakeholders,      which may include local employers, community stakeholders,      and local and State governments, to offer transitional      services, including employment and career counseling or job      placement, to help individuals in recovery from a substance      use disorder transition into the workforce.       ``(iii) The ability to partner with local stakeholders,      which may include local employers, community stakeholders,      and local and State governments, to assist employers with      informing their employees of the resources, such as treatment      options for a substance use disorder, that are available to      them.       ``(3) Use of funds.--An entity receiving a subgrant under      this subsection shall use the subgrant funds for more than      one of the following:       ``(A) To hire specialists with an expertise in treating      substance use disorders, including through residential      treatment, to assist with the treatment provided through a      subgrant under this subsection, which may include the use of      medication-assisted treatment.       ``(B) To provide wrap-around services to encourage      substance use disorder prevention, treatment, recovery, and      rehabilitation, with a focus on ensuring long-term recovery      and symptom remission.       ``(C) To help individuals transition from inpatient      treatment for a substance use disorder to the workforce by      providing--       ``(i) career services described in paragraph (2), and      training services described in paragraph (3), of section      134(c) of the Workforce Innovation and Opportunity Act (29      U.S.C. 3174(c)); and       ``(ii) related services described in section 134(a)(4)(D)      of such Act (42 U.S.C. 3174(a)(4)(D)).       ``(D) To implement innovative technologies to make      substance use disorder treatment more affordable and      accessible, which may include the use of telemedicine, and      may assist individuals in finding and maintaining employment      throughout recovery.       ``(E) To provide ongoing outpatient substance use disorder      treatment programs, including peer support meetings, for      individuals who have recovered or are in recovery from a      substance use disorder while they transition from receiving      treatment for such disorder to entering the workforce and      maintaining employment.       ``(F) To assist patients, including through hiring case      managers, care coordinators, or trained peer recovery      coaches, in recovery from a substance use disorder, including      through programs to provide services to develop daily living      skills, provide counseling, and provide housing assistance,      and through other appropriate Federal Government assistance      programs.       ``(G) With respect to an entity that provides the full      continuum of substance use disorder treatment services, which      may include detoxification, residential rehabilitation,      recovery housing, evidence-based treatments (which may      include the use of medication-assisted treatment),      counseling, and recovery supports, to expand such services to      include services that may include--       ``(i) short-term prevocational training services, such as      the development of learning skills, communication skills,      interviewing skills, punctuality, personal maintenance      skills, and professional conduct;       ``(ii) vocational training, which shall emphasize the      skills or knowledge necessary for a particular job function      or trade; and       ``(iii) care coordination throughout the short- and long-     term substance use disorder recovery process.       ``(H) Any other service determined by the Secretary as      necessary for achieving the goal of transitioning individuals      from treatment for substance use disorders to independent      living and the workforce or to encouraging substance use      disorder prevention in the workforce.       ``(d) Consultation.--The Secretary may, in carrying out the      pilot program under this section, consult with the Assistant      Secretary for Substance Use and Mental Health, the      Administrator of the Health Resources and Services      Administration, the Secretary of Labor, the Secretary of      Housing and Urban Development, and the Secretary of      Education.       ``(e) Reporting Requirements.--       ``(1) Reports to the secretary.--       ``(A) 5-year grants.--Not later than December 31, 2021,      each State that has received a grant under subsection (b)(1)      shall report to the Secretary on its progress and      effectiveness in meeting the objectives of the pilot program      under this section, including the progress and effectiveness      of the entities receiving subgrants under subsection (c) as      demonstrated through reports of such progress and      effectiveness submitted to the State by such entities.       ``(B) 1-year grants.--Not later than December 31 of the      fiscal year following the fiscal year for which a grant is      awarded under subsection (b)(2), the State or Indian tribe      receiving such grant shall report to the Secretary on its      progress and effectiveness in meeting the objectives of the      pilot program under this section, including the progress and      effectiveness of the entities receiving subgrants under      subsection (c) which may be demonstrated through reports of      such progress and effectiveness submitted to the State or      Indian tribe by such entities.       ``(2) Report to congress.--Not later than December 31,      2024, the Secretary shall submit a report to Congress,      including any applicable authorizing committee of the Senate      or House of Representatives, evaluating the grants awarded      under this section.       ``(f) Authorization of Appropriations.--There is authorized      to be appropriated $200,000,000, for each of fiscal years      2019 through 2023, to carry out this section. Out of such      amount appropriated for each such fiscal year--       ``(1) 75 percent shall be used to make grants under      subsection (b)(1); and       ``(2) 25 percent shall be used to make grants under      subsection (b)(2).''.     SEC. 3. TRANSITIONAL HOUSING SERVICES.       (a) In General.--Section 105(a) of the Housing and      Community Development Act of 1974 (42 U.S.C. 5305(a)) is      amended--       (1) in paragraph (25)(D), by striking ``and'' at the end;       (2) in paragraph (26), by striking the period at the end      and inserting ``; and''; and       (3) by adding at the end the following:       ``(27) providing temporary housing services to individuals      who are transitioning out of substance abuse treatment      programs for--       ``(A) a period of not more than 24 months or until the      individual secures permanent housing, whichever is earlier;      or       ``(B) such longer period as the Secretary determines      necessary.''.       (b) Additional CDBG Authorization of Appropriations.--       (1) Definition of covered entity.--In this subsection, the      term ``covered entity'' means--       (A) a State (as defined in section 102(a) of the Housing      and Community Development Act of 1974 (42 U.S.C. 5302(a))      that is among the 10 States with the highest rate of death      due to drug overdose per 100,000 people, based on data from      the Centers for Disease Control and Prevention for calendar      years 2013 through 2017; and       (B) any entitlement community located in a State described      in subparagraph (A).       (2) Authorization of appropriations.--In addition to any      amounts appropriated for the community development block      grant program under title I of the Housing and Community      Development Act of 1974 (42 U.S.C. 5301 et seq.), there are      authorized to be appropriated $25,000,000 for each of fiscal      years 2019 through 2023, to be allocated by the Secretary of      Housing and Urban Development on a competitive basis to      covered entities to carry out the activity described in      paragraph (27) of section 105(a) of such Act (42 U.S.C.      5305(a)), as added by subsection (a).       (3) Preferences.--In allocating amounts authorized to be      appropriated under paragraph (2), the Secretary of Housing      and Urban Development shall give priority to--       (A) States from among the States described in paragraph      (1)(A) with a combination of--       (i) the highest average rates of unemployment based on data      provided by the Bureau of Labor Statistics for calendar years      2013 through 2017;       (ii) the lowest average labor force participation rates      based on data provided by the Bureau of Labor Statistics for      calendar years 2013 through 2017; and       (iii) the highest prevalence of opioid use disorder based      on data provided by the Substance Abuse and Mental Health      Services Administration for calendar years 2013 through 2017      as may be available; and       (B) entitlement communities located in a State described in      clause (i), (ii), or (iii) of subparagraph (A).     SEC. 4. SUBSTANCE USE DISORDER TRANSITION ACTIVITIES.       (a) Reservations for State Activities.--Section 133(a)(1)      of the Workforce Innovation and Opportunity Act (29 U.S.C.      3173(a)(1)) is amended--       (1) by striking ``The Governor'' and inserting the      following:       ``(A) In general.--The Governor''; and       (2) by adding at the end the following:       ``(B) Substance use disorder transition activities.--       ``(i) Adult and dislocated funds.--Of the funds reserved as      required under section 128(a)(1) and subparagraph (A), the      Governor of a State with an application approved under      section 134(a)(4) may reserve a sum of not more than 5      percent of each of the amounts allotted to the State under      paragraphs (1)(B) and (2)(B) of section 132(b) for a fiscal      year for substance use disorder transition activities      described in section 134(a)(4). Notwithstanding sections      128(a)(2), 129(b), and 134(a), the Governor may not use an      amount allotted under section 127(b)(1)(C) for those      activities.       ``(ii) Vocational rehabilitation funds.--The Governor of a      State with such an approved application may reserve funds as      described in section 110(e) of the Rehabilitation Act of 1973      (29 U.S.C. 730(e)) for substance use disorder transition      activities described in section 134(a)(4).''.       (b) Statewide Employment and Training Activities.--       (1) In general.--Section 134(a)(1) of the Workforce      Innovation and Opportunity Act (29 U.S.C. 3174(a)(1)) is      amended--       (A) in subparagraph (A), by striking ``and'' at the end;       (B) in subparagraph (B), in the matter following clause      (ii), by striking the period and inserting ``; and''; and       (C) by adding at the end the following:       ``(C) as described in section 133(a)(1)(B), may be used for      substance use disorder transition activities as described in      paragraph (4), regardless of whether the funds were allotted      to the State under paragraph (1) or (2) of section 132(b).''.       (2) Substance use disorder transition activities.--Section      134(a) of the Workforce Innovation and Opportunity Act (29      U.S.C. 3174(a)) is amended by adding at the end the      following:       ``(4) Substance use disorder transition activities.--       ``(A) Definitions.--In this paragraph:       ``(i) Appropriate secretary.--The term `appropriate      Secretary' means--       ``(I) except as provided in subclause (II), the Secretary      of Labor; or       ``(II) if the application involves funds reserved under      section 110(e) of the Rehabilitation Act of 1973 (29 U.S.C.      730(e)), the Secretary of Labor and the Secretary of      Education.       ``(ii) Substance use disorder.--The term `substance use      disorder' means such a disorder within the meaning of the      term in title V of the Public Health Service Act (42 U.S.C.      290aa et seq.).       ``(iii) Substance use disorder transition activities.--The      term `substance use disorder transition activities' means      activities authorized under subparagraph (D) or (E).       ``(B) Eligible states.--To be eligible to use the funds      reserved under clause (i) or (ii) of section 133(a)(1)(B) for      substance use disorder transition activities described in      this paragraph, a State shall--       ``(i) submit to the appropriate Secretary an application      seeking flexibility to use the reserved funds for such      activities, and submit the application at such time, in such      manner, and containing such information as the appropriate      Secretary may require, including an assurance that the State      will award subgrants to entities on the basis of the ability      of the entities to provide the substance use disorder      transition activities involved, including any programs that      the entities propose to provide that lead to recognized      postsecondary credentials; and       ``(ii) obtain approval of the application.       ``(C) Subgrants.--An eligible State may use the funds      reserved under clause (i) or (ii) of section 133(a)(1)(B) to      make subgrants to one-stop operators and nonprofit      organizations, to provide services under subparagraph (D) and      (at the election of the State) subparagraph (E).       ``(D) Career services.--An entity that receives a subgrant      under subparagraph (C) shall use the subgrant funds to assist      individuals in recovery from a substance use disorder in      transitioning to the workforce, by providing career services      (such as the services described in section 134(c)(2)) and      related services, which may include 1 or more of--       ``(i) providing ongoing career counseling, both before and      after job placement, with a focus on individual employment      preferences while weighing the skill needs of industries in      the local area;       ``(ii) promoting systemic job development, by facilitating      voluntary programs and relationships between participants and      local employers to create potential employment opportunities;       ``(iii) providing benefits counseling--       ``(I) to ensure participants receive accurate information      regarding how employment will affect access to various      Federal programs, such as the Medicaid program established      under title XIX of the Social Security Act (42 U.S.C. 1396 et      seq.) and the supplemental security income program      established under title XVI of that Act (42 U.S.C. 1381 et      seq.); and       ``(II) to advise participants on ways to transition away      from the programs described in subclause (I) through      maintaining employment;       ``(iv) creating voluntary programs with employers to      establish a work and treatment arrangement, such as an      Employee Assistance Program, for employees in recovery from a      substance use disorder;       ``(v) providing educational materials or training to      employers to enable the employers to inform their employees      of the resources, such as treatment options for a substance      use disorder, that are available to them; and       ``(vi) any other career services that are determined to be      necessary by the appropriate Secretary and that would assist      individuals in recovery from a substance use disorder in      transitioning to the workforce.       ``(E) Training services.--An entity that receives a      subgrant under subparagraph (C) shall (at the election of the      State) use the subgrant funds to assist individuals in      recovery from a substance use disorder in transitioning to      the workforce, by providing training services.''.       (c) Administration.--Section 181 of the Workforce      Innovation and Opportunity Act (29 U.S.C. 3241) is amended--       (1) by redesignating subsection (g) as subsection (h); and       (2) by inserting after subsection (f) the following:       ``(g) Relationship to Other Laws.--       ``(1) Disability nondiscrimination law.--Subject to      paragraph (2), an employer that employs, or considers for      employment, any individual who receives services under this      section or under section 320B of the Public Health Service      Act shall have an absolute defense to any claim (including a      charge) of unlawful discrimination on the basis of disability      under a covered law, that alleges that the employer      discriminated against that individual (which may include      refusing to hire or terminating the employment of the      individual) based on alcohol addiction or past substance use      disorder for which the individual receives such services.       ``(2) Rule of construction.--Nothing in paragraph (1) shall      be construed to eliminate the duty of the employer, to an      employee who is an individual who receives such services, to      provide a reasonable accommodation for an alcohol disorder,      or a past substance use disorder, that is a disability under      a covered law.       ``(3) Definitions.--In this subsection:       ``(A) Covered law.--The term `covered law' means title I of      the Americans with Disabilities Act of 1990 (42 U.S.C. 12111      et seq.), title V of the Rehabilitation Act of 1973 (29      U.S.C. 791 et seq.), or a State law (including local law),      that prohibits discrimination on the basis of disability in      employment.       ``(B) Substance use disorder.--The term `substance use      disorder' means such a disorder within the meaning of the      term in title V of the Public Health Service Act (42 U.S.C.      290aa et seq.).''.       (d) Other Core Programs.--Section 110 of the Rehabilitation      Act of 1973 (29 U.S.C. 730) is amended by adding at the end      the following:       ``(e)(1) In the case of a transition State, from any State      allotment under subsection (a) for a fiscal year, the State      may reserve not more than 5 percent of the allotted funds for      substance use disorder transition activities described in      section 134(a)(4) of the Workforce Innovation and Opportunity      Act (29 U.S.C. 3174(a)(4)).       ``(2) In this section, the term `transition State' means a      State with an application approved under section 134(a)(4) of      the Workforce Innovation and Opportunity Act.''.                          ____________________